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Abstract
Background—Individual-level simulation models are valuable tools for comparing the impact
of clinical or public health interventions on population health and cost outcomes over time.
However, a key challenge is ensuring that outcome estimates correctly reflect real-world impacts.
Calibration to targets obtained from randomized trials may be insufficient if trials do not exist for
populations, time periods, or interventions of interest. Observational data can provide a wider
range of calibration targets, but requires methods to adjust for treatment-confounder feedback. We
propose the use of the parametric g-formula to estimate calibration targets and present a case-study
to demonstrate its application.
Methods—We used the parametric g-formula applied to data from the HIV-CAUSAL
Collaboration to estimate calibration targets for 7-year risks of CDC-defined AIDS and/or death
(AIDS/death) under 3 treatment initiation strategies. We compared these targets to projections
from the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model for treatment-
naïve individuals presenting to care in 1996–1999, 2000–2002, or 2003 or onwards.
Results—The parametric g-formula estimated a decreased risk of AIDS/death over time and with
earlier treatment. The uncalibrated CEPAC model successfully reproduced targets obtained via the
g-formula for baseline 1996–1999, but over-estimated calibration targets in contemporary
populations and failed to reproduce time trends in AIDS/death risk. Calibration to g-formula
targets improved CEPAC model fit for contemporary populations.
Conclusion—Individual-level simulation models are developed based on best available
information about disease processes in one or more populations of interest, but these processes can















change over time or between populations. The parametric g-formula provides a method for using
observational data to obtain valid calibration targets and enables updating of simulation model
inputs when randomized trials are not available.
Keywords
Agent-based model; calibration; HIV; g-formula
Introduction
Simulation models, such as agent-based or individual-level models, are often used to
estimate the population impact of implementing public health interventions or clinical
treatment strategies. Individual-level simulation models estimate (counterfactual) outcome
distributions under alternative policy or treatment strategies, and therefore answer causal
questions of the form: What would the outcome distribution in a population be if a particular
strategy had been implemented?
An individual-level simulation model is defined by parameters that describe the
relationships between treatments, outcomes, and other variables.(1) A key practical
challenge to creating these models is that these parameters cannot be directly estimated from
the population of interest. Otherwise, the outcome distributions could be estimated directly
from the data using causal inference techniques rather than via simulation. Instead, model
parameters typically need to be selected from a variety of sources and thus calibration
procedures are required before the model can be applied to the population of interest.(2–5)
Calibration is the process of comparing the simulation model results to outcome
distributions estimated using another analytic method, and has two steps. First, investigators
must identify appropriate benchmarks as calibration targets. Second, they must ensure that
the simulation model reproduces these targets in the population of interest.(4) A large
literature is devoted to the second step, including methods for searching the input parameter
space and determining goodness of fit.(6–9) Here, we focus on the first step, for which two
broad types of calibration targets may be of interest.
One possible target is the observed outcome distribution in the population of interest. This
can be estimated via a randomized trial or using observational data.(5) However, replicating
the observed outcomes requires knowing the distribution of treatment strategies in the
population so that these can be included in the analysis. This information may be difficult to
obtain except from randomized trials, where it is fixed by design. Because of this,
randomized trials are often seen as the gold-standard for obtaining calibration targets, but
there are several limitations to relying solely on randomized trials. First, a given trial
typically compares only a limited number of interventions, and the particular strategies of
interest for a model may not be included. Second, trials are often not available in the
population for which the simulation model is being calibrated, or may have been conducted
in a highly specific subset of the population and thus of limited generalizability.
A second possible target is the counterfactual outcome distribution under a single treatment
strategy selected from among the strategies present in the population. If sufficient
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observational data are available from the population of interest, this distribution can be
validly estimated using causal inference techniques, such as the parametric g-formula, which
is a generalization of standardization to settings with time-varying treatment and
confounders (10, 11) and similar in many aspects to individual-level simulation models.(12)
Here, we propose the application of the parametric g-formula to obtain a range of calibration
targets for individual-level simulation models when longitudinal data (on treatments,
outcomes, and confounders) is available in a population of interest. As a case study, we
apply the parametric g-formula to observational data to estimate calibration targets for the
Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model. We consider the
question of when to initiate antiretroviral therapy (ART) for people living with HIV.
The structure of this paper is as follows. We first describe the scenario of interest, the
observational dataset, and the parametric g-formula. We then describe the estimation of
calibration targets, the CEPAC model, and the calibration process. The calibration process is
presented in two stages: (I) estimation of the calibration targets via the parametric g0formula
and assessment of original parameterization fit, and (II) update of model parameters to
improve fit. We conclude with a discussion of the assumptions required for the parametric g-
formula to validly estimate the true counterfactual outcome distributions.
Methods
Scenario
We consider 3 treatment initiation strategies for people living with HIV individuals in
Europe and North America: (a) immediate ART initiation at diagnosis of HIV infection
(currently recommended in the US); (b) early ART initiation when CD4 count falls below
500 cells/μl; and (c) late ART initiation when CD4 count falls below 350 cells/μl. ART was
defined as a regimen of antiretroviral drugs including at least two nucleoside reverse
transcriptase inhibitors (NRTIs) and either one or more protease inhibitors (PI) or boosted
PIs, one non-nucleoside reverse transcriptase inhibitor (NNRTI), one integrase inhibitor
(INSTI), one entry or fusion inhibitor, or three or more NRTIs.
Until relatively recently, it was debated whether the benefits of early treatment initiation
might be offset by an increased risk of side effects and resistance that limits future treatment
options.(13–15) As of 2017, these strategies have been assessed in both observational
cohorts and randomized trials, and there is consensus that early initiation is preferable. We
use these strategies here as simple demonstration targets,(16–18) but the same approach
described here could be applied to a wider range of strategies or to more complex strategies,
such as scheduled treatment interruption plans or treatment switching strategies, provided
data exist.
We considered two types of outcomes: death and a combined outcome of death or AIDS
(defined as first diagnosis of an AIDS-defining opportunistic illness (19)). For each
outcome, we estimated two calibration targets: the 7-year outcome risk and the 7-year
survival curve under each treatment initiation strategy.
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We used data from the HIV-CAUSAL Collaboration (20, 21) to estimate our calibration
targets. This collaboration combines data from prospective cohorts of HIV-positive
individuals in Brazil, Canada, France, Greece, Netherlands, Spain, Switzerland, UK, and
USA. We excluded data from Brazil from our analyses because a separate parameterization
of the CEPAC model exists for Brazil. The estimates presented here are based on data
pooled in December 2015.
Our analyses included all HIV-positive individuals in the HIV-CAUSAL Collaboration aged
18 years or older, who were ART-naïve, did not have AIDS, were not pregnant, and had a
CD4 cell count and HIV RNA measurement within the past three months of baseline. The
start of follow-up for each individual was defined as the first month in which all eligibility
criteria were met during three baseline time periods: 1996–1999, 2000–2002, and 2003 and
onwards.
Each individual was followed until the earliest of death; censoring, defined as 12 months
after the last recorded CD4 cell count and HIV RNA measurements or pregnancy (if
known); or the study-specific administrative end of follow-up between February 2010 and
March 2013. Unlike in a previous application of the parametric g-formula to estimate the
impact of treatment initiation on survival in these data,(17) we did not require that baseline
occur within 6 months of HIV diagnosis because date of diagnosis is not used in CEPAC.
Parametric g-formula
We used the parametric g-formula to estimate our calibration targets adjusting for time-fixed
and time-varying confounders.(10, 11, 22) The implementation of the parametric g-formula
involves two steps: (I) parametric estimation of the joint distribution of covariates and
outcome over time; (II) simulation of the counterfactual outcome distribution under different
treatment strategies.(22) A brief description of each step follows. For more details we refer
readers to previous applications of the parametric g-formula. (17, 23–25)
Step I: Parametric estimation of the joint distribution of the data
As in previous analyses (16–18), we considered the following covariates: baseline CD4
count in cells/μl (<50, 50–99, 100–199, 200–349, 350–499, ≥500), HIV RNA log copies per
mL (<4, 4–5, >5), sex, race, geographical origin (Europe and the USA, sub-Saharan Africa,
rest of the world, unknown), transmission group (heterosexual, homosexual or bisexual,
injection drug user, and other/unknown), age in years (<35, 35–50, >50), calendar year
(<2000, 2000–04, 2005–10, 2011–13), and cohort; and time-varying CD4 cell count, HIV
RNA, and AIDS (when not an outcome). Importantly, these time-varying confounders are
also affected by prior treatment history leading to treatment-confounder feedback.
We next fit parametric regression models to the HIV-CAUSAL data to estimate the joint
distribution of the time-varying covariates, treatment initiation, and mortality over time. We
used logistic regression to model the time-varying indicators for death, AIDS, and treatment
initiation, and linear regression to model the natural logarithms of HIV RNA and CD4 cell
count. All models included the two most recent values of the time-varying covariates, as
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well as time since last CD4 count and HIV RNA measurements, and all baseline covariates.
Models for CD4 count and HIV RNA also included product terms for the number of months
since ART initiation.
Step II: Estimation of the counterfactual outcome distribution under several treatment
strategies
For each treatment strategy, we used the parametric models fit in Step I to generate a cohort
of the same size as the original data via Monte-Carlo simulation. At each time point, we
assigned treatment according to the treatment strategy. We then calculated the outcome
distribution in the simulated data.
We used non-parametric bootstraps with 500 samples to obtain 95% confidence intervals.
For each bootstrap, we took a random sample of the HIV-CASUAL data with replacement
and repeated the full process of Steps I –II. We then calculated the 95% confidence interval
based on the 2.5th and 97.5th percentiles of the bootstrap outcome estimates. All analyses
were conducted using the GFORMULA macro(26) in SAS 9.4.
As a sensitivity analysis, we estimated the outcome distributions under no intervention. That
is, we assigned treatment at each month based on the estimated conditional probability of
treatment observed in the HIV-CAUSAL data from Step 2.
CEPAC Model
We calibrated the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model.
The CEPAC model is a large, well-established individual-level simulation model that has
been used to assess cost-effectiveness of a range of clinical and public health policies aimed
at reducing the burden of disease and improving survival among people living with HIV(27–
29). Simulated individuals in CEPAC exist in one of three health states: chronic infection,
acute OIs, or death. Time-varying covariates, including CD4 count, HIV RNA level, age,
and sex, govern transitions between health states. There are three distinct probabilities that
govern mortality each month: the probability of chronic AIDS-related mortality, the
probability of acute OI-related mortality, and the probability of non-AIDS-related mortality.
Full specification of the model is provided on the CEPAC website (30) and elsewhere (28,
31).
The CEPAC model was originally designed using data from the Multicenter AIDS Cohort
Study (MACS) —a cohort study of HIV-positive men which began enrollment in 1984.(32)
CEPAC was originally calibrated to data from cohorts of people living with HIV in the US;
the prior calibration is described in detail elsewhere.(33) However, changes in available
treatments, testing strategies, and demographics of people living with HIV over time require
that the model be periodically recalibrated to ensure it continues to provide valid estimates
of survival and AIDS progression in contemporary settings. Here, we compared the
estimated outcome distributions from CEPAC to calibration targets obtained using the
parametric g-formula applied to HIV-CAUSAL data in the three baseline time periods.
Because more recent cohort data more accurately reflect the current clinical course of HIV
disease and treatment, we aimed for the recalibrated model to better fit the data from 2003
onwards.
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We simulated each treatment strategy and time period in CEPAC using 105 individuals. For
each simulated population, we used the observed baseline distributions of CD4 count (mean
and standard deviation), HIV RNA strata (% within strata), age (mean and standard
deviation), gender (% male), and transmission risk group from individuals in HIV-CAUSAL
who met the inclusion criteria within that baseline time period (Table 1, Appendix 1).
We used a previously published set of CEPAC parameter values for modeling AIDS-related
mortality, OI incidence, and changes to CD4 count and HIV RNA over time (Table 2).(28,
32, 34–36) Sex-stratified lifetables for the probability of non-AIDS-related mortality were
obtained from the Eurostat website.(37) Key parameter values are given in Table 2. For
more detail on these parameters, their sources, and how they govern transitions between
health states in CEPAC see Appendix 2.
We focused our calibration on two parameters, selected because their initial values had been
determined based on discussions with clinicians and other experts in the field, without a
substantial empirical evidence base. Specifically, we assessed the on-treatment multiplier for
OI incidence and the on-treatment multiplier for chronic AIDS-related mortality. In the
original CEPAC calibration, both multipliers were set to 1.0. We performed a grid search by
varying the on-treatment multipliers jointly between 1 and 0 by 0.2 units for a total of 36
calibration runs. We chose a simple grid search, rather than more formal search procedures
such as Nelder Mead, because our goal was chiefly to demonstrate the method of obtaining
calibration targets, rather than performing a full calibration of CEPAC.
We assessed the fit of the 7-year mortality and combined AIDS or mortality risks from the
calibration runs in comparison to the values of the calibration targets estimated using the
parametric g-formula applied to HIV-CAUSAL. Fit was determined based on the number of
treatment strategies and outcomes for which the CEPAC risk estimates were within the 95%
confidence intervals for the g-formula risks estimates. We also visually inspected survival
and AIDS-free survival curves produced by the calibration runs of CEPAC and those
obtained via the g-formula.
As sensitivity analyses, we compared the distributions of mean CD4 count and HIV RNA
over time estimated using CEPAC and the parametric g-formula (Appendix 3), and assessed
the impact on the CEPAC model results of varying a range of additional input parameters
(Appendix 4).
Results
Stage I: Comparison of the g-formula estimates with the original CEPAC model results
The HIV-CAUSAL Collaboration included 28,269 eligible individuals in 1996–1999,
25,433 in 2000–2002, and 78,093 in 2003 and onwards. Baseline characteristics are shown
in Table 1. The median duration of follow-up was 65 months (IQR: 27–151) in 1996–1999,
64 months (IQR: 27–126) in 2000–2002, and 36 months (IQR: 18–66) in 2003 and onwards.
Treatment initiation was similar in the three time periods— 63% of participants initiated
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ART during follow-up when baseline was between 1996 and 1999, 61% when baseline was
between 2000 and 2002, and 65% when baseline was in 2003 or later.
Table 3 compares the observed risks from HIV-CAUSAL with those estimated via the g-
formula under no intervention on treatment, and indicates that the g-formula provides a good
fit with the observational data. Additional sensitivity results for covariates are presented in
Figures A2–A5. The g-formula estimates for AIDS onset are somewhat further from the
observational data in the 1996–1999 baseline. This may be due to differences in confounders
early in the HIV epidemic, differences in the subset of individuals infected with HIV
presenting to care. A similar process could be used to assess the calibrated CEPAC model, if
the distribution of treatment initiation strategies in HIV-CAUSAL were known, by taking a
weighted average of CEPAC results over the treatment strategies followed in the data.
The calibration targets obtained from the g-formula under the three interventions of interest
are reported in Table 4. Using the g-formula, the estimated 7-year risk of mortality under
immediate ART initiation was 8.0% (95% CI: 7.5, 8.5) for baseline in 1996–1999, 6.9%
(95% CI: 6.4, 7.4) for baseline in 2000–2002, and 4.1% (95% CI: 3.9, 4.4) for baseline in
2003 and onwards (Table 4). The estimated 7-year risk of AIDS or death under immediate
ART initiation was 14.0% (95% CI: 13.4, 14.6) in 1996–1999, 12.6% (95% CI: 12.0, 13.3)
in 2000–2002, and 7.9% (95% CI: 7.6, 8.3) in 2003 and onwards (Table 4). Earlier treatment
initiation resulted in decreased risks for both outcomes, in all time periods.
The original CEPAC parameterization (using 1.0 for each of the on-treatment multipliers)
resulted in 7-year mortality risk estimates that were within the 95% confidence intervals of
the g-formula estimates under all treatment strategies for 1996–1999, but not for the 2000–
2002 or 2003 and onwards (Table 3, original CEPAC column). The CEPAC estimates of the
risk of combined AIDS/death outcome were higher than the g-formula estimates in all time
periods. Appendix Figures A1 and A2 display the estimated survival and AIDS-free survival
curves obtained via the g-formula and the original CEPAC model.
Stage II: Update of the simulation model parameters via calibration to g-formula targets
Figure 1 displays the survival and AIDS-free survival curves from all 36 CEPAC calibration
runs compared to the g-formula estimates from 2003 and onwards (the CEPAC estimates are
shown in grey and the observational estimates are shown in black). For the strategies of
immediate initiation and initiation at CD4 <500, multiple CEPAC calibration parameter sets
returned estimated survival curves that fit well with the observational estimates for both
outcomes, although survival and AIDS-free survival curves were somewhat steeper in the
first 6012 months of follow-up when using the g-formula (Figure 1). In contrast, for
initiation at CD4 <350, all CEPAC calibration parameter sets underestimated both survival
and AIDS-free survival compared with the observational data (Figure 1).
Figure 2 shows the 7-year mortality and combined AIDS or death risks in the 36 CEPAC
calibration runs. The top left corner of each sub-figure represents the 7-year risk when the
on-treatment multipliers for both OI incidence and chronic AIDS-mortality were set to 0, for
a given treatment strategy. This is equivalent to a situation in which individuals on ART are
not at risk for these outcomes. The bottom right corner of each sub-figure represents the
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scenario where both multipliers are set to 1, which would occur if the probability of OIs or
chronic AIDS-related mortality was the same regardless of treatment status. In each sub-
figure, the location in the heat map which is closest to the 7-year risk estimated from the
observational data is indicated by the black box; the area of the heat map which produces
estimates within the 95% confidence intervals estimated from the observational data is
enclosed in grey boxes.
The g-formula mortality risk at 7 years was reproducible for immediate initiation and
initiation at CD4 <500 when the multiplier for chronic AIDS-related mortality was close to
zero and the multiplier for OI incidence was at or below 0.2 (Figure 2). For initiation at CD4
<500 cells/μl the best fitting on-treatment multiplier for chronic AIDS-related mortality
changed to between 0.4 and 0.6. For initiation at CD4 <350, all calibration runs returned
estimates greater than the upper bound of the 95% confidence intervals from the g-formula
estimates for both outcomes.
Based on the 36 calibration runs, we fine-tuned the on-treatment parameter values by
applying a range of multipliers to the incidence of opportunistic infections and chronic
AIDS-related mortality in CEPAC for simulated patients on ART and projected overall
mortality and composite outcome of AIDS or death using this grid of possible multipliers.
We compared these projections to those generated by parametric g-formula estimates from
HIV-CAUSAL. Subsequently, we validated the newly calibrated CEPAC projections to
mortality estimates from the COHERE cohort.(38) This fine-tuning resulted in final
calibrated parameter values of 0.2 for OI incidence and 0.1 for chronic AIDS-related
mortality. We used these values to run CEPAC in all three time periods and present the risk
estimates obtained from this calibrated model under the three treatment initiation strategies
in Table 3.
The mortality risk and the combined AIDS or mortality risk estimates from the calibrated
CEPAC model were very close to the corresponding observational estimates for 2003 and
onwards under immediate treatment initiation and under initiation at CD4 counts above 500
cells/μl, but over-estimated the observational estimates under initiation below 350 cells/μl
(Table 3, calibrated column). Further calibration using the approach described here could be
performed to improve model performance for delayed treatment initiation strategies. Here,
we omit this calibration, since our goal is to demonstrate the process of using the g-formula
for calibration rather than present a full calibration of CEPAC.
Discussion
We have described a step-by-step procedure to identify counterfactual calibration targets
from observational data for use in calibrating an individual-level simulation model. To do
so, we estimated risks under several treatment strategies in an observational study (HIV-
CAUSAL Collaboration) using the parametric g-formula, identified model (CEPAC) input
parameters for which empirical data did not exist, and modified values of these parameters
to match the counterfactual outcome estimates.
The parametric g-formula allows us to estimate the outcome distributions under any
treatment strategy of interest followed by at least some individuals in the data. Unlike
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traditional regression approaches, the parametric g-formula is able to provide unbiased
outcome estimates even in the presence of treatment-confounder feedback – that is, even
when time-varying confounders are themselves affected by prior treatment.(11, 12, 22, 39)
A similar approach could be used to estimate counterfactual calibration targets under other
types of interventions, such as treatment interruption, monitoring of treatment efficacy, or
treatment switching, and is particularly useful when complex interventions which depend on
the evolution of time-varying markers of disease progression are of interest. For example,
the g-formula could be used to obtain calibration targets for a cardiovascular risk model
under a range of statin use strategies. Finally, even when trials with appropriate
interventions exist, non-adherence and loss to follow-up may make intention-to-treat
estimates insufficient. In these cases, obtaining appropriate calibration targets may require
adjustment for time-varying non-adherence or analysis of intermediate outcomes, and can
benefit from the use of methods such as the parametric g-formula. (10, 11, 22, 40, 41)
Our case study was based on the HIV-CAUSAL Collaboration, a consortium of
observational cohorts that collect longitudinal data on treatments, confounders, and
outcomes. The validity of this calibration procedure relies critically on the validity of the
parametric g-formula estimates. The parametric g-formula requires the assumptions of no
unmeasured treatment-outcome confounders and no misspecification of the parametric
models for treatment, confounders, and outcomes. Although unmeasured confounding is
always possible in observational studies, we adjusted our models for the main clinical
indications for treatment initiation during the study period such as CD4 count, HIV RNA,
and AIDS diagnosis, as well as for other potential confounders such as age, sex, geographic
origin, and mode of transmission. We also assessed the potential for model misspecification
in our parametric g-formula estimates by estimating the outcome distributions under the
observed distribution of treatment initiation strategies in HIV-CAUSAL, and found good
agreement between the data and our model results.
In our analysis, survival and AIDS-free survival both increased substantially between the
three baseline time periods when using the g-formula. This trend for improved survival of
people living with HIV has been observed elsewhere. (42) The original CEPAC
parameterization resulted in estimates that fit well with the g-formula estimates from
199601999, but not with those from most recent periods and CEPAC does not currently
model changes in parameters by calendar time. After calibration, the CEPAC model fit for
the 2003 onwards baseline period was greatly improved especially under immediate
treatment initiation and initiation at CD4 counts below 500 cells/μl.
The validity of the calibration also relies on the assumption that the population used for
calibration experiences the same treatment effects and outcome risks as the target population
for model inference. In our case, a majority of HIV-CAUSAL participants live in Europe,
while the CEPAC-US model has generally been used to estimate outcomes in the United
States. Differences in access to, and cascades of, care, underlying mortality risks, or
infectious disease transmission between these regions may explain some of the differences
we observed for the strategy of initiating treatment at CD4 counts below 350 cells/μl in
recent years.(42) Individuals who delayed treatment initiation in the post-2003 period are
likely to have presented to care later in the disease process, and those presenting late may
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differ between US and European populations. Therefore, estimates of calibration targets
based on HIV-CAUSAL for this strategy may be less appropriate to compare with US-
specific CEPAC estimates.
However, comparison of our calibrated CEPAC results with previous studies suggests that,
for individuals who are retained in care and on treatment, mortality risk may not differ
substantially between American and European populations. A study of a highly adherent
cohort of people living with HIV in the USA found a projected mean life expectancy of 69.3
years from the time of seroconversion,(43) whereas we estimate a mean life expectancy of
67.6 years using the newly calibrated CEPAC model. The calibrated CEPAC model also
matched previously published AIDS-related death rates from the COHERE collaboration
within a margin of 5 deaths per 10,000 people over a 2.7 year period. Five-year survival
estimates from the calibrated CEPAC model were within 2% of previously published HIV-
CAUSAL estimates for the strategy of immediate treatment initiation.(20)
Here, we used a simplified process for varying and assessing parameter fit – a grid search of
parameter space, and a comparison with 95% confidence intervals of the calibration targets.
More sophisticated search techniques and methods of assessing goodness of fit between
model outputs and calibration targets exist and could result in further improvements in the
calibration.(8, 44–48) In addition, in order to focus on the process of obtaining a range of
counterfactual calibration targets, we did not perform a full calibration to fit the model
results for all outcomes. However, we were able to greatly improve the fit of the CEPAC
model to the strategy of immediate treatment initiation for the period of 2003 onwards,
which is the strategy currently recommended for people living with HIV in the US and will
therefore likely serve as a comparison strategy for future analyses.(49)
In summary, the original CEPAC model performed well when compared to calibration
targets estimated from data starting in 1996–1999 – the time period for which the model was
developed – but recalibration of CEPAC parameters was required to obtain a fit with targets
estimated from 2003 onwards. This highlights the fact that populations can change over time
such that periodic recalibration of individual-level simulation models may be needed to
ensure that these models remain relevant over time. Similarly, recalibration of simulation
models may be needed when the target of inference changes to a new population.
Calibration must thus be an ongoing process to keep simulation models up-to-date and
relevant for the population, or populations, of interest. However, randomized controlled
trials will likely not be available for all populations or time periods of interest. The
parametric g-formula can provide a solution by increasing the availability of calibration
targets for these models.
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Appendix
1. HIV-CAUSAL Collaboration detailed baseline characteristics
The main text (Table 1) provides a summary of relevant HIV-CAUSAL cohort baseline
covariates necessary for parameterizing the CEPAC runs. We provide additional information
on the cohort profiles in Appendix Tables A1–A4 to provide further context to our results.
2. CEPAC input parameter sources
The main text (Table 2) provides the value of key CEPAC input parameters. We provide
additional information on the source of these parameters here to provide further context to
our results (Appendix Table A5).
Life table data were obtained based on average values for France, Greece, Netherlands,
Spain, Switzerland, and the UK. For 1996–1999, we used lifetables for the period 1996–
2013; for 2000–2002, we used 2000–2013; and for 2003 and onwards, 2003–2013. This
parameter is independent of treatment status.
Among individuals not on ART, CD4 cell counts decline each month (34, 35), and HIV
RNA remains at an individual-specific set point. The monthly probabilities of opportunistic
infections (OIs), chronic AIDS-related mortality, and acute OI-related mortality vary over
time based on current CD4 cell count in a given month. When not on ART, these
probabilities were obtained from the Multi-center AIDS Cohort Study (MACS). (32)
Use of ART affects simulated individuals through three main mechanisms: reducing in HIV
RNA, increasing CD4 cell count, and lowering the probabilities of OIs and of mortality. The
overall probability of virologic suppression (HIV RNA reduced to lowest stratum) within 6
months of treatment initiation is 86.0%.(36) To model heterogeneity of response to ART,
each individual is assigned a probability of treatment response, a measure of treatment
adherence, which is multiplied by the overall probability of virologic suppression to
determine the individual’s final probability of suppression. CD4 cell count increases by a
mean of 88 cells/μl in the first two months after treatment initiation, and a mean of 4 cells/μl
in the following months (36, 50). This CD4 cell count increase reduces the probability of OI
incidence, acute OI-related mortality, and chronic AIDS-related mortality, since these
probabilities are CD4-dependent. In addition, the probabilities of chronic AIDS-related
mortality, and OI incidence can be further adjusted by ‘on treatment’ multipliers stratified
by CD4 cell count and OI type (Pneumocystis pneumonia, Mycobacterium avium complex,
Toxoplasmosis, Cytomegalovirus, fungal infections, other OIs).
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Individuals who achieve virologic suppression have a monthly probability of treatment
failure, meaning that treatment no longer decreases the individual’s HIV RNA or increases
their CD4 count. Individuals who fail treatment will experience stable, or declining CD4
counts, and rising HIV RNA. At their next modeled clinic visit, these individuals can be
detected as failing and changed to a new ART regimen. There are 6 lines of ART available
in the model all with the same efficacy; individuals who fail all 6 lines remained on the last
failed ART regimen.
3. Survival and AIDS-free survival distributions by antiretroviral therapy
initiation strategy and baseline time period
Figures A1 and A2 show the survival and AIDS-free survival estimates over time for each
baseline time period and antiretroviral therapy initiation strategy, estimated using the
parametric g-formula applied to HIV-CAUSAL data and using the original CEPAC
parameterization.
4. Mean of study variables over time observed in HIV-CAUSAL and
estimated using the parametric g-formula
Figures A3 – A5 compare the means of treatment and study covariates over time estimated
using the parametric g-formula under the strategy “start treatment with the observed
conditional probability from the data” with the corresponding means observed in HIV-
CAUSAL. Though this comparison can detect model misspecification in the parametric g
formula, the lack of differences does not guarantee no model misspecification under other
strategies. If the distribution of treatment initiation strategies followed by individuals in
HIV-CAUSAL were known, a similar comparison could be made between CEPAC
estimates of treatment and covariates over time and the observed means. However,
parameterizing treatment to match the observed conditional probability distributions in a
simulation model may often not be feasible.
5. Progression of CD4 count and viral load
Some differences in survival and AIDS onset estimates between CEPAC and the g-formula
may be related to differences in progression of CD4 count and HIV RNA over time. Figure
A6 shows the estimated mean CD4 cell count and mean HIV RNA levels from the g-
formula applied to HIV-CAUSAL, and from CEPAC for the 2003 baseline, by treatment
initiation strategy, among individuals remaining alive at each month over follow-up. The
CEPAC runs shown here were obtained from the original parameterization, where the
treatment multipliers for OIs and for chronic AIDS-related mortality were both set to 1.
Mean CD4 counts improved over the three time periods and were higher when treatment
was initiated earlier for both CEPAC and the parametric g-formula. Mean CD4 counts
improved more rapidly and reached much higher levels by the end of follow-up in CEPAC
than with the parametric g-formula. Mean HIV RNA level decreased over the three time
periods and with earlier treatment initiation. HIV RNA levels were more variable in the
parametric g-formula estimates than in CEPAC, especially in the earlier baseline periods.
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6. Additional parameters assessed in calibration
We first varied a range of parameters to identify those to which the CEPAC results were
most sensitive. Specifically, we varied the 1-month probabilities of OI incidence and chronic
AIDS-related mortality when not on-treatment, the on-treatment multipliers for OI incidence
and chronic AIDS-related mortality, the highest CD4 count stratum at which OIs and/or
chronic AIDS-related mortality could occur while on treatment, the probability of acute OI-
related mortality (on and off treatment), the probability of treatment response, and the
probability of treatment failure after suppression. To assess the importance of specific
baseline characteristics, we also varied the distributions for baseline CD4 cell counts and
HIV RNA strata, and assessed using transmission risk group distributions and sex-stratified
lifetables from the USA only (28).
Changes to the on-treatment multipliers for OIs and chronic AIDS-related mortality,
distribution of probability of response, and probability of treatment failure were the most
effective in reducing the discrepancies between the CEPAC and observational estimates. We
selected the on-treatment multipliers for our main calibration example since empirical data
regarding the appropriate value of these parameters did not exist.
7. Contributors to the HIV-CAUSAL Collaboration
AMACS
Steering Committee: Antoniadou A., Chrysos G., Daikos G., Gargalianos Kakolyris P.,
Gogos HA., Katsarou O., Kordossis T., Lazanas M., Nikolaidis P., Panos G., Paparizos V.,
Paraskevis D., Sambatakou H., Skoutelis A., Touloumi G. (Chair). Coordinating Center:
Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical
School, Greece (Touloumi G., Pantazis N., Vourli G., Gountas I., Gioukari V.)
Participating Centers: 4th Dept of Internal Medicine, Athens Medical School, Attikon
University Hospital (Antoniadou A, Papadopoulos A, Petrikkos G); Infectious Disease Unit,
“Tzaneio” General Hospital of Pireaus (Chrysos G, Paraskeva D, Hatziastros P); 1st Dept of
Propedeutic Medicine, Athens University, Medical School “Laikon” General Hopsital
(Daikos G, Psichogiou M); 1st Dept of Medicine, Infectious Diseases Unit, “G. Gennimatas”
Athens General Hospital (Gargalianos Kakolyris P, Xylomenos G); 1st Dept of Internal
Medicine, Infectious Diseases Section, Patras University Hospital (Gogos HA, Marangos
MN, Panos G); Haemophilia Centre, 2nd Blood Transfusion Centre, “Laikon” Athens
General Hospital (Katsarou O, Kouramba A, Ioannidou P); AIDS Unit, Dept of
Pathophysiology, “Laikon” Athens General Hospital and Athens University, Medical School
(Kordossis T, Kontos A); Infectious Diseases Unit, Red Cross General Hospital of Athens
(Lazanas M, Chini M, Tsogas N); 1st Dept of Internal Medicine, Infectious Diseases
Devision, AHEPA University Hospital, Aristotle University HIV Unit (Nikolaidis P,
Kolaras P, Metallidis S); 2nd Internal Medicine Clinic, 1st IKA (Panos G, Haratsis G);
AIDS Unit, Clinic of Venereologic & Dermatologic Diseases, Athens University, Medical
School, Syngros Hospital (Paparizos V, Leuow K, Kourkounti S); HIV Unit, 2nd Dpt. of
Internal Medicine, Athens University, Medical School, Hippokration General Hospital
(Sambatakou H, Mariolis I); Infectious Diseases & HIV Division, Dept of Internal
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Medicine, Evaggelismos Athens General Hospital (Skoutelis A, Papastamopoulos V,
Baraboutis I).
AQUITAINE
Principal investigator: Pr F. Dabis. Scientific committee: Prs F. Bonnet, D. Breilh, F. Dabis,
M. Dupon, G. Chêne, H. Fleury, D. Malvy, P. Mercié, I. Pellegrin, P. Morlat, D. Neau, JL.
Pellegrin, R. Thiébaut; Drs S. Bouchet, V. Gaborieau, D. Lacoste, S. Tchamgoué.
Epidemiology and biostatistics: Prs G. Chêne, F. Dabis, R. Thiébaut, Drs M. Bruyand, S.
Lawson Ayayi, L. Wittkop. Clinical and biological hospital units: Bordeaux University
Hospital: Pr P. Morlat (Pr F. Bonnet, Drs N. Bernard, M. Hessamfar, D. Lacoste, MA.
Vandenhende); Pr M. Dupon (Drs FA. Dauchy, H. Dutronc), Pr M. Longy Boursier (Pr P.
Mercié, Drs P. Duffau, J. Roger Schmeltz), Pr D. Malvy (Drs T. Pistone, MC Receveur), Pr
D. Neau (Drs C. Cazanave, A. Ochoa, MO. Vareil), Pr JL. Pellegrin (Pr JF. Viallard, Drs C.
Greib, E. Lazaro); Pr H. Fleury (Pr ME. Lafon, Drs S. Reigadas, P. Trimoulet); Pr D. Breilh;
Pr M. Molimard (Drs S. Bouchet, K. Titier); Pr JF. Moreau (Dr I. Pellegrin); Drs F.
Haramburu, G. Miremont Salamé. Arcachon Hospital: Dr A. Dupont. Dax Hospital: Dr Y.
Gerard (Drs L. Caunègre, K. André). Bayonne Hospital: Dr F. Bonnal (Drs S. Farbos, MC.
Gemain). Libourne Hospital: Dr J. Ceccaldi (Dr S. Tchamgoué). Mont de Marsan Hospital:
Dr S. De Witte (Dr C. Courtault). Pau Hospital: Drs E. Monlun (Dr V. Gaborieau).
Périgueux Hospital: Dr P. Lataste (Dr JP. Meraud). Villeneuve-sur-Lot Hospital: Dr I.
Chossat. Permanent team: MJ. Blaizeau, M. Bruyand, V. Conte, M. Decoin, J. Delaune, S.
Delveaux, F. Diarra, C. D’Ivernois, A. Frosch, S. Geffard, C. Hannapier, S. Lawson-Ayayi,
E. Lenaud, O. Leleux, F. Le Marec, J. Leray, I. Louis, G. Palmer, A. Pougetoux, X. Sicard,
D. Touchard B. Uwamaliya Nziyumvira.
ATHENA
The ATHENA database is maintained by Stichting HIV Monitoring and supported by a
grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for
Infectious Disease Control of the National Institute for Public Health and the Environment.
CLINICAL CENTRES (* denotes site coordinating physician). Academic Medical Centre of
the University of Amsterdam: HIV treating physicians: J.M. Prins*, T.W. Kuijpers, H.J.
Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. Reiss, T. van der Poll,
F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, W.J. Wiersinga, M. van der Valk, A.
Goorhuis, J.W. Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J. van Eden, A.M.H.
van Hes, M. Mutschelknauss, H.E. Nobel, F.J.J. Pijnappel, A.M. Weijsenfeld. HIV clinical
virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. Berkhout, M.T.E.
Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter Ziekenhuis, Goes: HIV
treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. Baas, L.
Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina
Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. HIV
nurse consultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/chemists: A.R.
Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. Elisabeth-TweeSteden
Ziekenhuis, Tilburg: HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV
nurse consultants: R. van Erve, B.A.F.M. de Kruijf-van de Wiel, S.Keelan-Pfaf, B. van der
Ven. Data collection: B.A.F.M. de Kruijf-van de Wiel, B. van der Ven. HIV clinical
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virologists/chemists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Emma Kinderziekenhuis: HIV
nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: HIV
treating physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, B.J.A.
Rijnders, C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs. HIV nurse consultants: N.
Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld. Data collection: H.J. van den
Berg-Cameron, F.B. Bruinsma-Broekman, J. de Groot, M. de Zeeuw-de Man. HIV clinical
virologists/chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas.
Erasmus MC–Sophia, Rotterdam: HIV treating physicians: G.J.A. Driessen, A.M.C. van
Rossum. HIV nurse consultants: L.C. van der Knaap, E. Visser. Flevoziekenhuis, Almere:
HIV treating physicians: J. Branger*, A. Rijkeboer-Mes. HIV nurse consultant and data
collection: C.J.H.M. Duijf-van de Ven. HagaZiekenhuis, Den Haag: HIV treating
physicians: E.F. Schippers*, C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J.
Geilings. Data collection: G. van der Hut. HIV clinical virologist/chemist: P.F.H. Franck.
HIV Focus Centrum (DC Klinieken): HIV treating physicians: A. van Eeden*. HIV nurse
consultants: W. Brokking, M. Groot, L.J.M. Elsenburg. HIV clinical virologists/chemists:
M. Damen, I.S. Kwa. Isala, Zwolle: HIV treating physicians: P.H.P. Groeneveld*, J.W.
Bouwhuis. HIV nurse consultants: J.F. van den Berg, A.G.W. van Hulzen. Data collection:
G.L. van der Bliek, P.C.J. Bor. HIV clinical virologists/chemists: P. Bloembergen, M.J.H.M.
Wolfhagen, G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, Leiden: HIV treating
physicians: F.P. Kroon*, M.G.J. de Boer, H. Jolink, A.M. Vollaard. HIV nurse consultants:
W. Dorama, N. van Holten. HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels.
Maasstad Ziekenhuis, Rotterdam: HIV treating physicians: J.G. den Hollander*, K. Pogany,
A. Roukens. HIV nurse consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman,
C. Tearno. Data collection: M. Bezemer, T. van Niekerk. HIV clinical virologists/chemists:
O. Pontesilli. Maastricht UMC+, Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L.
Oude Lashof, D. Posthouwer. HIV nurse consultants: R.P. Ackens, J. Schippers, R.
Vergoossen. Data collection: B. Weijenberg-Maes. HIV clinical virologists/chemists: I.H.M.
van Loo, T.R.A. Havenith. MCH-Bronovo, Den Haag: HIV treating physicians: E.M.S.
Leyten*, L.B.S. Gelinck. HIV nurse consultants: A.Y. van Hartingsveld, C. Meerkerk, G.S.
Wildenbeest. HIV clinical virologists/chemists: J.A.E.M. Mutsaers, S.Q. van Veen. MC
Slotervaart, Amsterdam: HIV treating physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N.
Lauw. HIV nurse consultants: M.C. van Broekhuizen, H. Paap, D.J. Vlasblom. HIV clinical
virologists/chemists: P.H.M. Smits. MC Zuiderzee, Lelystad: HIV treating physicians: S.
Weijer*, R. El Moussaoui. HIV nurse consultant: A.S. Bosma. Medisch Centrum
Leeuwarden, Leeuwarden: HIV treating physicians: M.G.A.van Vonderen*, D.P.F. van
Houte, L.M. Kampschreur. HIV nurse consultants: K. Dijkstra, S. Faber. HIV clinical
virologists/chemists: J Weel. Medisch Spectrum Twente, Enschede: HIV treating
physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse consultants: M. van der Burg van de
Plas, H. Heins. Data collection: E. Lucas. Noordwest Ziekenhuisgroep, Alkmaar: HIV
treating physicians: W. Kortmann*, G. van Twillert*, J.W.T. Cohen Stuart, B.M.W.
Diederen, R. Renckens. HIV nurse consultant and data collection: D. Ruiter-Pronk, F.A. van
Truijen-Oud. HIV clinical virologists/chemists: W. A. van der Reijden, R. Jansen. OLVG,
Amsterdam: HIV treating physicians: K. Brinkman*, G.E.L. van den Berk, W.L. Blok,
P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. HIV nurse consultants: C.J.
Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, M. Spelbrink, H.
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Sulman, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. Kwa. Data
collection: E. Witte. Radboudumc, Nijmegen: HIV treating physicians: R. van Crevel*, M.
Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse
consultants: M. Albers, K.J.T. Grintjes-Huisman, M. Marneef, A. Hairwassers. HIV clinical
virologists/chemists: J. Rahamat-Langendoen. HIV clinical pharmacology consultant: D.
Burger. Rijnstate, Arnhem: HIV treating physicians: E.H. Gisolf*, R.J. Hassing, M.
Claassen. HIV nurse consultants: G. ter Beest, P.H.M. van Bentum, N. Langebeek. HIV
clinical virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne Gasthuis, Haarlem:
HIV treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants:
L.M.M. van der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical
virologists/chemists: W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal.
Medisch Centrum Jan van Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen.
HIV nurse consultants: M. van Wijk. Universitair Medisch Centrum Groningen, Groningen:
HIV treating physicians: W.F.W. Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, H.
Scholvinck, Y. Stienstra, C.L. Vermont, K.R. Wilting. HIV nurse consultants: A. Boonstra,
H. de Groot de Jonge, P.A. van der Meulen, D.A. de Weerd. HIV clinical virologists/
chemists: H.G.M. Niesters, C.C. van Leer Buter, M. Knoester. Universitair Medisch
Centrum Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, J.E. Arends, R.E.
Barth, A.H.W. Bruns, P.M. Ellerbroek, T. Mudrikova, J.J. Oosterheert, E.M. Schadd,
M.W.M. Wassenberg, M.A.D. van Zoelen. HIV nurse consultants: K. Aarsman, D.H.M. van
Elst-Laurijssen, E.E.B. van Oers-Hazelzet. Data collection: M. van Berkel. HIV clinical
virologists/chemists: R. Schuurman, F. Verduyn-Lunel, A.M.J. Wensing. VUmc,
Amsterdam: HIV treating physicians: E.J.G. Peters*, M.A. van Agtmael, M. Bomers, J. de
Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. HIV clinical virologists/chemists:
C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-Grauls. Wilhelmina
Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, T.F.W. Wolfs,
L.J. Bont. HIV nurse consultants: N. Nauta. COORDINATING CENTRE. Director: P.
Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S.
Boender. Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data
monitoring: D. Bergsma, A. de Lang, S. Grivell, A. Jansen, M.J. Rademaker, M. Raethke, R.
Meijering, S. Schnörr. Data collection: L. de Groot, M. van den Akker, Y. Bakker, E.
Claessen, A. El Berkaoui, J. Koops, E. Kruijne, C. Lodewijk, L. Munjishvili, B. Peeck, C.
Ree, R. Regtop, Y. Ruijs, T. Rutkens, L. van de Sande, M. Schoorl, A. Timmerman, E.
Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra. Patient registration: B. Tuk.
CoRIS/CoRIS-MD
Steering committee: S Moreno, J del Amo, D Dalmau, ML Navarro, MI González, JL
Blanco, F Garcia, R Rubio, JA Iribarren, F Gutiérrez, F Vidal, J Berenguer, J González.
Field work, data management, and statistical analyses: P Sobrino, I Jarrín, B Alejos, V
Hernando, D Alvarez, C Moreno. Participating centres: Hospital General Universitario de
Alicante, Alicante (J Portilla, E Merino, S Reus, V Boix, L Giner, C Gadea, I Portilla, M
Pampliega, M Díez, JC Rodríguez, J Sánchez Payá) ; Hospital Universitari de Bellvitge,
Badalona (D Podzamczer, E Ferrer, A Imaz, E Van Den Eyncle, S Di Yacovo, M Sumoy);
Hospital Universitario de Canarias, Santa Cruz de Tenerife (JL Gómez, J Hernández, MR
Alemán, MM Alonso, MI Hernández, F Díaz Flores, D García, R Pelazas) ; Hospital
Murray et al. Page 16













Universitario Central de Asturias, Oviedo (V Asensi, E Valle, JA Cartón); Hospital Clínico
San Carlos, Madrid (V Estrada, MJ Téllez, J Vergas, E Pérez Cecila); Hospital Doce de
Octubre, Madrid (R Rubio, F Pulido, O Bisbal, M Matarranz, M Lagarde, R Rubio Martín,
A Hernando, L Bermejo, L Dominguez); Hospital Universitario Donostia, San Sebastián (JA
Iribarren, J Arrizabalaga, MJ Aramburu, X Camino, F Rodríguez Arrondo, MÁ von
Wichmann, L Pascual, MÁ Goenaga, MJ Bustinduy, H Azkune, M Ibarguren, M Aguado, M
Umerez); Hospital General Universitario de Elche, Elche (F Gutiérrez, M Masiá, C López, S
Padilla, A Navarro, F Montolio, C Robledano, JG Colomé, A Adsuar, R Pascual, F Carlos,
M Martinez, J Llenas, M Fernández, E García); Hospital Germans Trías i Pujol, Badalona
(R Muga, J Tor, A Sanvisens); Hospital General Universitario Gregorio Marañón, Madrid (J
Berenguer, JC López Bernaldo de Quirós, P Miralles, I Gutiérrez, M Ramírez, B Padilla, P
Gijón, A Carrero, T Aldamiz Echevarría, F Tejerina, FJ Parras, P Balsalobre, C Diez;
Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili,
Tarragona (F Vidal, J Peraire, C Viladés, S Veloso, M Vargas, M López Dupla, M Olona, A
Aguilar, JJ Sirvent, V Alba, O Calavia; Hospital Universitario La Fe, Valencia (M Montero,
J Lacruz, M Blanes, E Calabuig, S Cuellar, J López, M Salavert) ; Hospital Universitario La
Paz/IdiPaz, Madrid (J González, I Bernardino, JR Arribas, ML Montes, JM Peña, B Arribas,
JM Castro, FJ Zamora, I Pérez, M Estébanez, S García, M Díaz, NS Alcáriz, J Mingorance,
D Montero, A González, MI de José); Hospital de la Princesa, Madrid (I de los Santos, J
Sanz, A Salas, C Sarriá, A Gómez Berrocal, L Garcia Fraile; Hospital San Pedro-CIBIR,
Logroño (JA Oteo, JR Blanco, V Ibarra, L Metola, M Sanz, L Pérez-Martínez) ; Hospital
Universitario Miguel Servet, Zaragoza (A Pascual, C Ramos, P Arazo, D Gil); Hospital
Universitari Mutua de Terrassa, Terrassa (D Dalmau, A Jaén, M Cairó, D Irigoyen, Q
Jordano, M Xercavins, J Martinez-Lacasa, P Velli, R Font, M Sanmartí, L Ibáñez; Complejo
Hospitalario de Navarra, Pamplona (M Rivero, MI Casado, JA Díaz, J Uriz, J Repáraz, C
Irigoyen, MJ Arraiza); Hospital Parc Taulí, Sabadell (F Segura, MJ Amengual, G Navarro,
M Sala, M Cervantes, V Pineda, V Segura, M Navarro, E Antón, MM Nogueras); Hospital
Ramón y Cajal, Madrid (S Moreno, JL Casado, F Dronda, A Moreno, MJ Pérez Elías, D
López, C Gutiérrez, N Madrid, A Lamas, P Martí, A de Diaz, S Serrrano, L Donat); Hospital
Reina Sofía, Murcia (A Cano, E Bernal, Á Muñoz); Hospital San Cecilio, Granada (F
García, J Hernández, A Peña, L Muñoz, J Parra, M Alvarez, N Chueca, V Guillot, D
Vinuesa, JA Fernández); Centro Sanitario Sandoval, Madrid (J Del Romero, C Rodríguez, T
Puerta, JC Carrió, M Vera, J Ballesteros); Hospital de la Santa Creu i Sant Pau, Barcelona (P
Domingo, MA Sambeat, K Lamarca, G Mateo, M Gutiérrez, I Fernández); Hospital
Universitario Santiago de Compostela, Santiago de Compostela (A Antela, E Losada);
Hospital Son Espases, Palma de Mallorca (M Riera, M Peñaranda, M Leyes, MA Ribas, AA
Campins, C Vidal, L Gil, F Fanjul, C Marinescu); Hospital Universitari Vall d´Hebron,
Barcelona (E Ribera); Hospital Virgen de la Victoria, Málaga (J Santos, M Márquez, I
Viciana, R Palacios, I Pérez, CM González); Hospital Universitario Virgen del Rocío,
Sevilla (P Viciana, M Leal, LF López Cortés, N Espinosa); Hospital Universitario de
Basurto, Bilbao (J Muñoz, M Zuriñe Zubero, J Mirena, S Ibarra, O Ferrero, J López de
Munain, MM Cámara, I López, M de la Peña); Hospital Universitario Infanta Sofía, San
Sebastián de los Reyes (I Suárez-García, E Malmierca); Hospital Universitario Costa del
Sol, Marbella (J Olalla, A del Arco, J de la Torre, JL Prada, Z Caracuel); Hospital del
Poniente, El Ejido (AM Lopez-Lirola, AB Lozano, E Fernández, I Pérez, JM Fernández);
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Hospital Universitario Santa Lucia, Cartagena (OJ Martínez, FJ Vera, L Martínez, J García,
B Alcaraz, A Jimeno); INIBIC-Complejo Hospitalario Universitario de A Coruña, A Coruña
(E Poveda, B Pernas, A Mena, M Grandal, A Castro, JD Pedreira); Hospital Clínico
Universitario Virgen de la Arrixaca, Murcia (C Galera, H Albendin, A Iborra, A Moreno,
MA Campillo, A Vidal); Hospital Marina Baixa, Villajoyosa (C Amador, F Pasquau, J Ena,
C Benito, V Fenoll); Complejo Hospitalario de Jaén, Jaén (MO Mohamed Balghata, MA
Gómez); Hospital San Agustín de Avilés, Avilés (MA de Zarraga, ME Rivas); Fundación
Jiménez Diaz,Madrid (M Górgolas).
FHDH-ANRS CO4
Scientific committee: S Abgrall, F Barin, M Bentata, E Billaud, F Boué, C Burty, A Cabié,
D Costagliola, L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, L Fredouille-Heripret, J
Gasnault, C Gaud, J Gilquin, S Grabar, C. Katlama, MA Khuong, JM Lang, AS Lascaux, O
Launay, A Mahamat, M Mary-Krause, S Matheron, JL Meynard, J Pavie, G Pialoux, F
Pilorgé, I Poizot-Martin, C Pradier, J Reynes, E Rouveix, A Simon, P Tattevin, H Tissot-
Dupont, JP Viard, N Viget. DMI2 coordinating center: French Ministry of Health (Valérie
Salomon), Technical Hospitalization Information Agency, ATIH (N Jacquemet). Statistical
analysis center: U943 INSERM et UPMC (S Abgrall, D Costagliola, S Grabar, M Guiguet,
E Lanoy, L Lièvre, M Mary-Krause, H Selinger-Leneman), INSERM Transfert (JM
Lacombe, V Potard). COREVIH: Paris area: Corevih Ile de France Centre (GH Pitié
Salpétrière: F Bricaire, S Herson, C Katlama, A Simon; Hôpital Saint-Antoine: N
Desplanque, PM Girard, JL Meynard, MC Meyohas, O Picard; Hôpital Tenon: J Cadranel, C
Mayaud, G Pialoux), Corevih Ile de France Est (Hôpital Saint-Louis: JP Clauvel, JM
Decazes, L Gerard, JM Molina; GH Lariboisière-Fernand Widal: M Diemer, P Sellier;
Hôpital Avicenne: M Bentata, P Honoré; Hôpital Jean Verdier: V Jeantils, S Tassi; Hôpital
Delafontaine: D Mechali, B Taverne), Corevih Ile de France Nord (Hôpital Bichat-Claude
Bernard: E Bouvet, B Crickx, JL Ecobichon, S Matheron, C Picard-Dahan, P Yeni), Corevih
Ile de France Ouest (Hôpital Ambroise Paré: H Berthé, C Dupont; Hôpital Louis Mourier: C
Chandemerle, E Mortier; Hôpital Raymond Poincaré: P de Truchis), Corevih Ile de France
Sud (Hôpital Européen Georges Pompidou: D Tisne-Dessus, L Weiss; GH Tarnier-Cochin:
D Salmon; Hôpital Saint-Joseph: I Auperin, J Gilquin; Hôpital Necker adultes: L Roudière,
JP Viard; Hôpital Antoine Béclère: F Boué, R Fior; Hôpital de Bicêtre: JF Delfraissy, C
Goujard; Hôpital Henri Mondor: C Jung, Ph Lesprit; Hôpital Paul Brousse: D Vittecoq).
Outside Paris area: Corevih Alsace (CHRU de Strasbourg: P Fraisse, JM Lang, D Rey; CH
de Mulhouse: G Beck-Wirth), Corevih de l’Arc Alpin (CHU de Grenoble: JP Stahl, P
Lecercq), Corevih Auvergne-Loire (CHU de Clermont-Ferrand: F Gourdon, H Laurichesse;
CHRU de Saint-Etienne: A Fresard, F Lucht); Corevih Basse-Normandie (CHRU de Caen:
C Bazin, R Verdon), Corevih Bourgogne (CHRU de Dijon: P Chavanet), Corevih Bretagne
(CHU de Rennes: C Arvieux, C Michelet), Corevih Centre (CHRU de Tours: P Choutet, A
Goudeau, MF Maître), Corevih Franche-Comté (CHRU de Besançon: B Hoen; CH de
Belfort: P Eglinger, JP Faller); Corevih Haute-Normandie (CHRU de Rouen: F Borsa-
Lebas, F Caron), Corevih Languedoc-Roussillon (CHU de Montpellier: J Reynes; CHG de
Nîmes: JP Daures), Corevih Lorraine (Nancy Hôpital de Brabois: T May, C Rabaud; CHRU
de Reims: JL Berger, G Rémy), Corevih de Midi-Pyrénées (Toulouse CHU Purpan: E Arlet-
Suau, L Cuzin, P Massip, MF Thiercelin Legrand; Toulouse Hôpital la Grave: G Pontonnier;
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Toulouse CHU Rangueil), Corevih Nord Pas de Calais (CH de Tourcoing: N Viget, Y
Yasdanpanah), Corevih PACA Est (Nice Hôpital Archet 1: P Dellamonica, C Pradier, P
Pugliese; CHG Antibes-Juan les Pins: K Aleksandrowicz, D Quinsat), Corevih PACA Ouest
(Marseille Hôpital de la Conception: I Ravaux, H Tissot-Dupont; Marseille Hôpital Nord: JP
Delmont, J Moreau; Marseille Institut Paoli Calmettes: JA Gastaut; Marseille Hôpital
Sainte-Marguerite: I Poizot Martin, F Retornaz, J Soubeyrand; Marseille Centre
pénitentiaire des Baumettes: A Galinier, JM Ruiz; CHG d’Aix-En-Provence: T Allegre, PA
Blanc; CH d’Arles: D Bonnet-Montchardon; CH d’Avignon: G Lepeu; CH de Digne Les
Bains: P Granet-Brunello; CH de Gap: JP Esterni, L Pelissier; CH de Martigues: R Cohen-
Valensi, M Nezri; CHI de Toulon: S Chadapaud, A Laffeuillade), Corevih Pays de la Loire
(CHRU de Nantes: E Billaud, F Raffi), Corevih de la Vallée du Rhône (Lyon Hôpital de la
Croix-Rousse: A Boibieux, D Peyramond; Lyon Hôpital Edouard Herriot: JM Livrozet, JL
Touraine; Lyon Hôtel-Dieu: L Cotte, C Trepo). Overseas: Corevih Guadeloupe (CHRU de
Pointe-à-Pitre: M Strobel; CH Saint-Martin: F Bissuel), Corevih Guyane (CHG de Cayenne:
R Pradinaud, M Sobesky), Corevih Martinique (CHRU de Fort-de-France: A Cabié),
Corevih de La Réunion (CHD Félix Guyon: C Gaud, M Contant).
Swiss HIV Cohort Study (SHCS): Aubert V, Barth J, Battegay M, Bernasconi E, Böni J,
Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Egger M, Elzi L, Fehr J, Fellay J,
Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M,
Günthard H (President of the SHCS), Haerry D (deputy of “Positive Council”), Hasse B,
Hirsch HH, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, Kouyos R,
Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D,
Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head
of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schmid P, Schultze
D, Schöni-Affolter F, Schüpbach J, Speck R, Staehelin C, Tarr P, Telenti A, Trkola A,
Vernazza P, Weber R, Yerly S.
GEMES
Principal Investigator: R Muga/S Pérez-Hoyos. Data analysis center: S Pérez-Hoyos, A
Schiaffino Centro Nacional de Epidemiología: J del Amo, D Alvarez, S Monge.
Participating centres: Cohorte del Hospital Germans Trias I Pujol, Badalona (R Muga, A
Sanvisens, B Clotet, J Tor, F Bolao, I Rivas, D Fuster), Cohorte de Madrid-Sandoval (J del
Romero, P Raposo, C Rodríguez, M Vera), Cohorte de los CIPS de la Comunidad
Valenciana (I Hurtado, J Belda, E Fernandez, I Alastrue, C Santos, T Tasa, A Juan, J
Trullen), Cohortes de los CAS, de las Prisiones de Cataluña y de hemofílicos del Hospital
Vall d´Hebron, Barcelona (P Garcia de Olalla, J Cayla, E Masdeu, H Knobel, JM Mirò, MA
Sambeat, R Guerrero, E Rivera), Cohorte de hemofílicos del Hospital La Paz, Madrid (M
Quintana, C Gonzalez), Cohorte de Navarra (J Castilla, M Guevara). Laboratory: C de
Mendoza, N Zahonero, M Ortíz.
IPEC
Principal investigators: Beatriz Grinsztejn and Valdiléa G Veloso. Collaborators: Lara
Coelho, Raquel De Boni, Dayse P Campos, Antonio G Pacheco, Paula M Luz, Rodrigo de
C. Moreira, Ronaldo I Moreira, Ruth K Friedman, Marilia Santini Oliveira, Sandra W
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Cardoso, Monica Derrico, Sayonara R Ribeiro, Leonardo Eksterman, Hugo Perazzo,
Estevão P. Nunes, Maria R. Guimarães, Rodolfo Castro, Marcelo Ribeiro-Alves, Katia
Lemos, Jose Roberto Grangeiro, Mario Sergio Pereira, Luciane Velasque, Jose Ricardo
Coutinho, Angela Cristina Andrade, Juliana Netto, Rodrigo Otavio Escada, Desiree Gomes
Santos, Flaviana Pavan.
PISCIS
Coordinators: J. Casabona, Centre d’Estudis Epidemiològics les Infeccions de Transmissió
Sexual i Sida de Catalunya (CEEISCAT), Jose M. Miró (Hospital Clínic de Barcelona
Idibaps, Universitat de Barcelona, Barcelona, Spain). Field coordinator: A. Gallois
(CEEISCAT). Steering committee: J. Casabona, A. Gallois, A. Esteve (CEEISCAT), Jose
M. Miró (Hospital Clínic de Barcelona-Idibaps, Universitat de Barcelona), D. Podzamczer
(Hospital de Bellvitge de Barcelona), J. Murillas (Hospital Son Espases). Scientific
committee: JM Gatell, C. Manzardo (Hospital Clínic-Idibaps, Universitat de Barcelona), C.
Tural, B. Clotet (Hospital Universitari Germans Trias i Pujol, Universitat Autónoma de
Barcelona), E. Ferrer (Hospital de Bellvitge), M. Riera (Hospital Son Espases), F. Segura,
G. Navarro (Corporación Sanitaria Universitaria Parc Taulí, Universitad Autónoma de
Barcelona), L. Force (Hospital de Mataró), J. Vilaró (Hospital General de Vic), A. Masabeu
(Hospital de Palamós), I. García (Hospital General d’Hospitalet), M.Guadarrama (Hospital
Alt Penedès de Vilafranca), C. Cifuentes (Hospital Son Llàtzer), D. Dalmau, À. Jaen
(Hospital Universitari Mútua de Terrassa), C. Agustí (CEEISCAT). Data Management and
statistical analysis: A. Esteve, A. Montoliu (CEEISCAT), I. Pérez (Hospital Clínic-Idibaps,
Universitat de Barcelona). Technical support: I. Pérez (Hospital Clínic de Barcelona-
Idibaps, Universitat de Barcelona), Freyra Gargoulas (Hospital Son Espases and Hospital
Son Llàtzer). Clinicians involved: JL Blanco, F. Garcia-Alcaide, E. Martínez, J. Mallolas,
M. López-Dieguez, JF García-Goez, (Hospital Clínic-Idibaps, Universitat de Barcelona), G.
Sirera, J. Romeu, A. Jou. E. Negredo, C. Miranda, MC Capitan (Hospital Universitari
Germans Trias i Pujol, Universitat Autónoma de Barcelona), M. Saumoy, A. Imaz, JM
Tiraboschi, O. Murillo, F. Bolao, C. Peña, C. Cabellos, M Masó, A. Vila (Hospital
Universitari de Bellvitge), M. Sala, M. Cervantes, Mª Jose Amengual, M. Navarro, E Penelo
(Corporación Sanitaria Universitaria Parc Taulí, Universitad Autónoma de Barcelona), P.
Barrufet, G. Bejarano (Hospital de Mataró, Barcelona), J. Molina, M. Guadarrama, M.
Alvaro, J. Mercadal (Hospital Alt Penedès de Vilafranca). Civil society representatives:
Juanse Fernández (Comitè 1er de Desembre), Jesús E. Ospina (RedVIH).
PRIMO
JM Molina, B Loze (St Louis-Paris), P Morlat, M Bonarek, F Bonnet, C Nouts, I Louis (St
André-Bordeaux), F Raffi, V Reliquet, F Sauser, C Biron, O Mounoury, H Hue, D Brosseau
(Hotel Dieu-Nantes), JF Delfraissy, C Goujard, J Ghosn, MT Rannou (Bicêtre – Le Kremlin
Bicêtre), JF Bergmann, E Badsi, A Rami, M Diemer, MParrinello (Lariboisière-Paris), PM
Girard, D Samanon-Bollens, P Campa, M Tourneur, N Desplanques (St Antoine - Paris), JM
Livrozet, F Jeanblanc, P Chiarello, D Makhloufi (E Herriot - Lyon), AP Blanc, T Allègre
(CHG - Aix en Provence), J Reynes, V Baillat, V Lemoing, C Merle de Boever, C Tramoni
(Gui de Chauliac-Montpellier), A Cabié, G Sobesky, S Abel, V Beaujolais (CHU - Fort de
France), G Pialoux, L Slama, C Chakvetadze, V Berrebi (Tenon - Paris), P Yeni, E Bouvet, I
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Fournier, J Gerbe (Bichat - Paris), C Trepo, K Koffi, C Augustin-Normand, P Miailhes, V
Thoirain, C Brochier (Hotel Dieu - Lyon), R Thomas, F Souala, M Ratajczak (Pontchaillou -
Rennes), J Beytoux, C Jacomet, F Gourdon (G Montpied – Clermont-Ferrand), E Rouveix, S
Morelon, C Dupont, C Olivier (A Paré - Boulogne), O Lortholary, B Dupont, JP Viard, A
Maignan (Necker - Paris), JM Ragnaud, I Raymond (Pellegrin - Bordeaux), C Leport, C
Jadand, C Jestin, P Longuet, S Boucherit (Bichat - Paris), D Sereni, C Lascoux, F Prevoteau
(St Louis - Paris), A Sobel, Y Levy, JD Lelièvre, AS Lascaux, S Dominguez, C Dumont (H
Mondor - Créteil), H Aumaître, B Delmas, M Saada, M Medus (St Jean - Perpignan), L
Guillevin, D Salmon, T Tahi (Cochin - Paris), Y Yazdanpanah, S Pavel, MC Marien (CH
Dron - Tourcoing), B Drenou, G Beck-Wirth, C Beck, M Benomar (E Muller - Mulhouse),
C Katlama, R Tubiana, H Ait Mohand, A Chermak, S Ben Abdallah (Pitié-Salpétrière -
Paris), M Bentata, F Touam, (Avicenne - Bobigny), B Hoen, C Drobacheff, A Folzer (St
Jacques - Besançon), P Massip, M Obadia, L Prudhomme, E Bonnet, F Balzarin (Purpan *
Toulouse), E Pichard, JM Chennebault, P Fialaire, J Loison (CHR - Angers), P Galanaud, F
Boué, D Bornarel (Béclère Clamart), R Verdon, C Bazin, M Six, P Ferret (CHR Côte de
Nacre - Caen), L Weiss, D Batisse, G Gonzales-Canali, D Tisne-Dessus (HEGP - Paris), A
Devidas, P Chevojon, I Turpault (Corbeil Essonnes), A Lafeuillade, A Cheret, G Philip
(Chalucet - Toulon), P Morel, J Timsit (St Louis - Paris), S Herson, N Amirat, A Simon, C
Brancion (Pitié - Salpétrière - Paris), J Cabane, O Picard, J Tredup, N Desplanques (St
Antoine - Paris), A Stein, I Ravault (La Conception - Marseille), C Chavanet, M Buisson, S
Treuvetot (Bocage - Dijon), P Choutet, P Nau, F Bastides (Bretonneau - Tours), T May, L
Boyer, S Wassoumbou (CHU - Nancy), E Oksenhendeler, L Gérard (St Louis - Paris), L
Bernard, P De Truchis, H Berthé (R Poincaré - Garches), Y Domart, D Merrien (CH -
Compiègne), A Greder Belan, (A Mignot - Le Chesnay), M Gayraud, L Bodard, A Meudec
(IMM Jourdan - Paris), C Beuscart, C Daniel, E Pape (La Beauchée - St Brieuc), P
Vinceneux, AM Simonpoli, A Zeng (L Mourier - Colombes), L Fournier (M Jacquet -
Melun), JG Fuzibet, C Sohn, E Rosenthal, M Quaranta (L’Archet - Nice), P Dellamonica, S
Chaillou, M Sabah (L’Archet - Nice), B Audhuy, A Schieber (L Pasteur - Colmar), P
Moreau, M Niault, O Vaillant (Bretagne Sud - Lorient), G Huchon, A Compagnucci (Hotel-
Dieu - Paris), I De Lacroix Szmania, L Richier (Intercommunal - Créteil), I Lamaury
(Abymes - Pointe à Pitre), F Saint-Dizier, D Garipuy (Ducuing – Toulouse), JA Gastaut, MP
Drogoul, I Poizot Martin, G Fabre (St Marguerite – Marseille), G Lambert de Cursay, B
Abraham, C Perino (CH - Brives), P Lagarde, F David (CH - Lagny), J Roche-Sicot, JL
Saraux, A Leprêtre (S Veil-Eaubonne), B Fampin, A Uludag, AS Morin (Beaujon – Clichy),
O Bletry, D Zucman (Foch - Suresnes), A Regnier (CH - Vichy), JJ Girard (CH - Loches),
DT Quinsat, L Heripret (CH - Antibes), F Grihon (Haute Vallée de l’Oise-Noyon), D
Houlbert (CH - Alençon), M Ruel, K Chemlal (CH - Nanterre), F Caron, Y Debab (C
Nicolle - Rouen), F Tremollieres, V Perronne (F Quesnay - Mantes La Jolie), G Lepeu, B
Slama (H Duffaut - Avignon), P Perré (Les Oudairies - La Roche sur Yon), C Miodovski
(Paris), G Guermonprez, A Dulioust (CMC Bligny - Briis s/Forges), P Boudon, D Malbec
(R Ballanger - Aulnay s/bois), O Patey, C Semaille (CH - Villeneuve St Georges), J Deville,
G Remy, I Béguinot (CH - Reims).
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Hopital Antoine Beclere, Clamart (P Galanaud, F Boue, V Chambrin, C Pignon, GA Estocq,
A Levy), Hopital de Bicetre, Le Kremlin Bicetre (JF Delfraissy, C Goujard, M Duracinsky,
P Le Bras, MS Ngussan, D Peretti, N Medintzeff, T Lambert, O Segeral, P Lezeau, Y
Laurian), Hopital Europeen Georges Pompidou, Paris (L Weiss, M Buisson, C Piketty, M
Karmochkine, D Batisse, M Eliaszewitch, D Jayle, D Tisne- Dessus, M Kazatchkine),
Hopital Bichat Claude Bernard, Paris (C Leport, U Colasante, C Jadand, C Jestin, X Duval,
W Nouaouia, S Boucherit, JL Vilde), Hopital Saint Antoine, Paris (PM Girard, D Bollens, D
Binet, B Diallo, MC Meyohas, L Fonquernie, JL Lagneau), Hopital Cochin, Paris (D
Salmon, LGuillevin, T Tahi, O Launay, MP Pietrie, D Sicard, N Stieltjes, J Michot), Hopital
Henri Mondor, Creteil (A Sobel, Y Levy, F Bourdillon, AS Lascaux, JD Lelievre, C
Dumont), Hopital Necker, Paris (B Dupont, G Obenga, JP Viard, A Maignan), Hopital Paul
Brousse, Villjuif (D Vittecoq, L Escaut, C Bolliot), Hopital Pitie Salpetriere, Paris (F
Bricaire, C Katlama, L Schneider, S Herson, A Simon, M Iguertsira), Hopital de la
Conception, Marseille (A Stein, C Tomei, I Ravaux, C Dhiver, H Tissot Dupont, A Vallon, J
Gallais, H Gallais), Hopital Sainte Marguerite, Marseille (JA Gastaut, MP Drogoul, G
Fabre), Hopital de L’Archet, Nice (P Dellamonica, J Durant, V Mondain, I Perbost, JP
Cassuto, JM Karsenti, H Venti, JG Fuzibet, E Rosenthal, C Ceppi, M Quaranta), Hopital
Avicenne, Bobigny (JA Krivitsky, M Bentata, O Bouchaud, P Honore), Hopital Saint Louis,
Paris (D Sereni, C Lascoux, J Delgado), ACCTES/Hopital Necker, Paris (C Rouzioux, M
Burgard, L Boufassa), Hopital Mignot, Le Chesnay (J Peynet).
SOUTHERN ALBERTA CLINIC COHORT
John Gill, Hartmut Krentz and Ron Read (Southern Alberta Clinic, Calgary, Canada).
SWISS HIV COHORT STUDY
Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini
M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the
Clinical and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS),
Haerry D (deputy of “Positive Council”), Hasse B, Hirsch HH, Hoffmann M, Hösli I,
Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti
G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni
P, Rauch A (Chairman of the Scientific Board), Rudin C (Chairman of the Mother & Child
Substudy), Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle M, Tarr P,
Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.
UK CHIC
Steering Committee: Jonathan Ainsworth, Sris Allan, Jane Anderson, Abdel Babiker, David
Chadwick, Valerie Delpech, David Dunn, Martin Fisher, Brian Gazzard, Richard Gilson,
Mark Gompels, Phillip Hay, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg,
Clifford Leen, Fabiola Martin, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Andrew
Phillips, Deenan Pillay, Frank Post, Jillian Pritchard, Caroline Sabin, Achim Schwenk,
Anjum Tariq, Roy Trevelion, John Walsh. Central Co ordination: University College
London (Teresa Hill, Sophie Jose, Andrew Phillips, Caroline Sabin); Medical Research
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Council Clinical Trials Unit at UCL (MRC CTU at UCL), London (David Dunn, Adam
Glabay). Participating Centres: Brighton and Sussex University Hospitals NHS Trust (M
Fisher, N Perry, S Tilbury, E Youssef, D Churchill); Chelsea and Westminster Hospital
NHS Foundation Trust, London (B Gazzard, M Nelson, R Everett, D Asboe, S Mandalia);
King’s College Hospital NHS Foundation Trust, London (F Post, H Korat, C Taylor, Z
Gleisner, F Ibrahim, L Campbell); Mortimer Market Centre, University College London (R
Gilson, N Brima, I Williams); Royal Free NHS Foundation Trust/University College
London (M Johnson, M Youle, F Lampe, C Smith, R Tsintas, C Chaloner, S Hutchinson, C
Sabin, A Phillips T Hill, S Jose); Imperial College Healthcare NHS Trust, London (J Walsh,
N Mackie, A Winston, J Weber, F Ramzan, M Carder); Barts and The London NHS Trust,
London (C Orkin, J Lynch, J Hand, C de Souza); Homerton University Hospital NHS Trust,
London (J Anderson, S Munshi); North Middlesex University Hospital NHS Trust, London
(J Ainsworth, A Schwenk, S Miller, C Wood); The Lothian University Hospitals NHS Trust,
Edinburgh (C Leen, A Wilson, S Morris); North Bristol NHS Trust (M Gompels, S Allan);
Leicester, University Hospitals of Leicester NHS Trust (A Palfreeman, K Memon, A
Lewszuk); Middlesbrough, South Tees Hospitals NHS Foundation Trust, (D Chadwick, E
Cope, J Gibson); Woolwich, Lewisham and Greenwich NHS Trust (S Kegg, P Main, Dr
Mitchell, Dr Hunter), St. George’s Healthcare NHS Trust (P Hay, M Dhillon); York
Teaching Hospital NHS Foundation Trust (F Martin, S Russell Sharpe); Coventry,
University Hospitals Coventry and Warwickshire NHS Trust (S Allan, A Harte, S Clay);
Wolverhampton, The Royal Wolverhampton Hospitals NHS Trust (A Tariq, H Spencer, R
Jones); Chertsey, Ashford and St.Peter’s Hospitals NHS Foundation Trust (J Pritchard, S
Cumming, C Atkinson); Public Health England, London (V Delpech); HIV i-base (R
Trevelion).
UK Register of HIV Seroconverters
Steering Committee: Andrew Phillips (Chair), University College London (UCL), London;
Abdel Babiker, MRC CTU, London; Valerie Delpech, Public Health England, London;
Sarah Fidler, St. Mary’s Hospital, London; Martin Fisher, Brighton & Sussex University
Hospitals NHS Trust, Brighton; Julie Fox, Guys and St Thomas’ NHS Trust/Kings College,
London; Richard Gilson, West London Centre for Sexual Health, London; David Goldberg,
Health Protection Scotland, Glasgow; David Hawkins, Chelsea & Westminster NHS Trust,
London; Anne Johnson, UCL, London; Margaret Johnson, UCL and Royal Free NHS Trust,
London; Ken McLean, West London Centre for Sexual Health, London; Deenan Pillay,
UCL, London; Frank Post, Kings College, London. Collaborating clinical centres: N
Kennedy, Monklands Hospital, Airdrie; J Pritchard, Ashford Hospital, Ashford; U Andrady,
Ysbyty Gwynedd, Bangor; N Rajda, North Hampshire Hospital, Basingstoke; C Donnelly, S
McKernan, Royal Victoria Hospital, Belfast; S Drake, G Gilleran, D White, Birmingham
Heartlands Hospital, Birmingham; J Ross, J Harding, R Faville, Whittall Street Clinic,
Birmingham; J Sweeney, P Flegg, S Toomer, Blackpool Victoria Hospital, Blackpool; H
Wilding, R Woodward, Royal Bournemouth Hospital, Bournemouth; G Dean, C
Richardson, N Perry, Royal Sussex County Hospital, Brighton; M Gompels, L Jennings,
Southmead Hospital, Bristol; D Bansaal, Queens Hospital, Burton upon Trent; M Browing,
L Connolly, Cardiff Royal Infirmary, Cardiff; B Stanley, North Cumbria Acute Hospitals
NHS Trust, Carlisle; S Estreich, A Magdy, St. Helier Hospital, Carshalton; C O’Mahony,
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Countess of Chester Hospital, Chester; P Fraser, Chesterfield & North Derbyshire Royal
Hospital, Chesterfield; SPR Jebakumar, Essex County Hospital, Colchester; L David,
Coventry & Warwickshire Hospital, Coventry; R Mette, Mayday University Hospital,
Croydon; H Summerfield, Weymouth Community Hospital, Dorset; M Evans, Ninewells
Hospital, Dundee; C White, University Hospital of North Durham, Durham; R Robertson,
Muirhouse Medical Group, Edinburgh; C Lean, S Morris, Western General Hospital,
Edinburgh; A Winter, Gartnavel General Hospital & Glasgow Royal Infirmary, Glasgow; S
Faulkner, Gloucestershire Royal Hospital, Gloucester; B Goorney, Salford Hope Hospital,
Greater Manchester; L Howard, Farnham Road Hospital, Guildford; I Fairley, C Stemp,
Harrogate Hospital, Harrogate; L Short, Huddersfield Royal Infirmary, Huddersfield; M
gomez, F young, St Mary’s Hospital Isle of Wight; M Roberts, S Green, Kidderminster
General Hospital, Kidderminster; K Sivakumar, The Queen Elizabeth Hospital, King’s
Lynn; J Minton, A Siminoni, Leeds General Infirmary, Leeds; J Calderwood, D
Greenhough, J Minton, St. James Hospital, Leeds; C DeSouza, Lisa Muthern, C Orkin, Barts
& The London NHS Trust, London; S Murphy, M Truvedi, Central Middlesex Hospital,
London; K McLean, Charing Cross Hospital, London; D Hawkins, C Higgs, A Moyes,
Chelsea & Westminster Hospital, London; S Antonucci, S McCormack, Dean Street Clinic,
London; W Lynn, Ealing Hospital, London; M Bevan, J Fox, A Teague, Guy’s & St.
Thomas NHS Trust, London; J Anderson, S Mguni, Homerton Hospital, London; F Post, L
Campbell, E Wandolo King’s College Hospital, London; C Mazhude, H Russell, Lewisham
University Hospital, London; R Gilson, G Carrick, C Young Mortimer Market Centre,
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Hernán, K Kraemer, J Lim, S Maisto, P Miller, L Mole, P O’Connor, R Papas, JM Robins,
C Rinaldo, M Roberts, J Samet, B Tierney, J Whittle.
Figure A1.
Survival distribution stratified by baseline time period and antiretroviral therapy initiation
strategy estimated using the parametric g-formula applied to HIV-CAUSAL data and using
the original CEPAC parameterization. (a)Baseline from Jan 1, 1996 – Dec 31, 1999,
parametric g-formula; (b) Baseline from Jan 1, 2000 – Dec 31, 2002, parametric g formula;
(c) Baseline on or after Jan 1, 2003, parametric g-formula; (d) Baseline from Jan 1, 1996 –
Dec 31, 1999, CEPAC; (e) Baseline from Jan 1, 2000 – Dec 31, 2002, CEPAC; (f) Baseline
on or after Jan 1, 2003, CEPAC. All CEPAC estimates use initial parameterization of 1.0 for
on-ART multipliers of opportunistic infection incidence and chronic AIDS-related mortality.
CEPAC: Cost-Effectiveness of Preventing AIDS Complications model
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AIDS-free survival baseline time period and antiretroviral therapy initiation strategy
estimated using the parametric g-formula applied to HIV-CAUSAL data and using the
original CEPAC parameterization. (a) Baseline from Jan 1, 1996 – Dec 31, 1999, parametric
g-formula; (b) Baseline from Jan 1, 2000 – Dec 31, 2002, parametric g-formula; (c) Baseline
on or after Jan 1, 2003, parametric g-formula; (d) Baseline from Jan 1, 1996 – Dec 31, 1999,
CEPAC; (e) Baseline from Jan 1, 2000 – Dec 31, 2002, CEPAC; (f) Baseline on or after Jan
1, 2003, CEPAC. All CEPAC estimates use initial parameterization of 1.0 for on-ART
multipliers of opportunistic infection incidence and chronic AIDS-related mortality.
CEPAC: Cost-Effectiveness of Preventing AIDS Complications model
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Mean of the main study variables under no intervention when outcome is mortality:
observed (solid line) and estimated via the parametric g-formula (dotted line). HIV-
CAUSAL Collaboration, on or after Jan 1, 2003. (a) Cumulative incidence of death; (b)
Cumulative incidence of AIDS; (c) Mean proportion on treatment; (d) Mean CD4 count,
natural log scale; (e) Mean HIV RNA.
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Mean of the main study variables under no intervention when outcome is mortality:
observed (solid line) and estimated via the parametric g-formula (dotted line). HIV-
CAUSAL Collaboration, Jan 1, 2000 – Dec 31, 2002. (a) Cumulative incidence of death; (b)
Cumulative incidence of AIDS; (c) Mean proportion on treatment; (d) Mean CD4 count,
natural log scale; (e) Mean HIV RNA, natural log scale.
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Mean of the main study variables under no intervention when outcome is mortality:
observed (solid line) and estimated via the parametric g-formula (dotted line). HIV-
CAUSAL Collaboration, Jan 1, 1996 – Dec 31, 1999. (a) Cumulative incidence of death; (b)
Cumulative incidence of AIDS; (c) Mean proportion on treatment; (d) Mean CD4 count,
natural log scale; (e) Mean HIV RNA, natural log scale.
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Mean of CD4 count and HIV RNA under intervention
Estimating using CEPAC and via the parametric g-formula in HIV-CAUSAL Collaboration,
using baseline on or after Jan 1, 2003. All CEPAC estimates use initial parameterization of
1.0 for multipliers. (a) Mean CD4 count in HIV-CAUSAL (cells/μl); (b) Mean CD4 count in
CEPAC (cells/μl); (c) Mean HIV RNA in HIV-CAUSAL (copies/mL); (d) Mean HIV RNA
in CEPAC (copies/mL).
Table A1
Distribution of HIV-CAUSAL data by country of cohort, %
Cohort Jan 1 1996 to Dec 31 1999 Jan 1 2000 to Dec 31 2002 On or after Jan 1 2003
Canada 1.0 0.9 1.4
France 50.0 39.5 27.0
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Cohort Jan 1 1996 to Dec 31 1999 Jan 1 2000 to Dec 31 2002 On or after Jan 1 2003
Greece 2.3 2.0 4.8
Netherlands 2.0 6.0 12.6
Spain 7.0 10.6 17.4
Switzerland 8.6 6.2 4.1
UK 16.2 21.3 24.4
USA 12.7 13.5 9.7
Table A2
Detailed baseline characteristics, HIV-CAUSAL Collaboration: Jan 1, 1996 Dec 31, 1999



























CD4 cell count, cells/
μl
<50 1,519 9,781.25 0.84 53 (15, 145) 354 36.2 201 20.6
50–100 1,172 7,693.50 0.84 53 (17, 149) 209 27.2 144 18.7
100–200 2,979 19,403.50 0.80 51 (17, 142) 374 19.3 259 13.4
200–350 6,295 40,830.67 0.72 50 (17, 141) 485 11.9 375 9.2
350–500 6,612 41,859.00 0.62 47 (17, 135) 414 9.9 343 8.2
>500 9,692 55,965.08 0.46 40 (15, 117) 525 9.4 445 8.0
HIV RNA, copies/mL <10,000 10,187 56,539.58 0.45 36 (14, 110) 571 10.1 492 8.7
10,000–100,000 11,498 74,533.67 0.67 50 (17, 141) 900 12.1 686 9.2
>100,000 6,584 44,459.75 0.82 58 (19, 146) 890 20.0 589 13.3
Sex Men 21,361 136,126.17 0.65 48 (17, 139) 2,059 15.1 1,542 11.3
Women 6,908 39,406.83 0.57 41 (15, 114) 302 7.7 225 5.7
Age, years <35 13,835 81,588.00 0.59 42 (16, 119) 572 7.0 404 5.0
35–50 11,745 75,364.92 0.65 48 (16, 142) 1,152 15.3 854 11.3
>50 2,689 18,580.08 0.73 64 (19, 150) 637 34.3 509 27.4
Transmission group Heterosexual 8,401 52,008.58 0.64 47 (17, 130) 402 7.7 303 5.8
Homosexual or bisexual 9,197 69,782.58 0.67 70 (22, 162) 545 7.8 396 5.7
Injecting drug user 5,132 22,833.33 0.52 29 (11, 72) 429 18.8 316 13.8
Other or unknown 5,539 30,908.50 0.65 37 (13, 117) 985 31.9 752 24.3
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Detailed baseline characteristics, HIV-CAUSAL Collaboration: baseline, Jan 1, 2000 Dec
31, 2002



























CD4 cell count, cells/
μl
<50 1,375 8,071.00 0.88 58 (18, 122) 253 31.3 171 21.2
50–100 1,109 6,494.00 0.87 57 (19, 121) 166 25.6 122 18.8
100–200 2,645 14,813.58 0.83 52 (18, 118) 271 18.3 224 15.1
200–350 5,678 32,327.08 0.72 51 (17, 121) 342 10.6 283 8.8
350–500 5,922 34,159.50 0.58 49 (18, 122) 326 9.5 275 8.1
>500 8,704 46,830.08 0.42 43 (17, 112) 350 7.5 312 6.7
HIV RNA, copies/mL <10,000 8,685 44,931.42 0.43 40 (15, 108) 403 9.0 367 8.2
10,000–100,000 10,631 60,588.25 0.65 50 (18, 120) 683 11.3 554 9.1
>100,000 6,117 37,175.58 0.82 61 (21, 124) 622 16.7 466 12.5
Sex Men 19156 132819.7 0.63 52 (19, 123) 1,471 13.4 1,194 10.9
Women 5554 34921.58 0.57 39 (15, 98) 237 7.3 193 5.9
Age, years <35 18,803 110,041.17 0.57 42 (17, 108) 282 4.9 222 3.9
35 50 6,630 32,654.08 0.63 52 (18, 123) 784 11.9 628 9.5
>50 11,014 57,643.25 0.72 63 (19, 124) 642 33.7 537 28.5
Transmission group Heterosexual 11,270 65,988.17 0.61 44 (17, 108) 310 6.5 242 5.1
Homosexual or bisexual 3,149 19,063.83 0.64 75 (26, 138) 305 5.3 241 4.2
Injecting drug user 8,953 47,355.00 0.49 26 (11, 60) 242 20.8 205 17.6
Other or unknown 8,280 57,125.67 0.65 42 (15, 116) 851 32.0 699 26.3
Table A4
Detailed baseline characteristics, HIV-CAUSAL Collaboration: On or after Jan 1, 2003



























CD4 cell count, cells/
μl
<50 3,847 13,935.50 0.87 35 (15, 65) 347 24.9 237 17.0
50–100 3,279 12,158.25 0.89 35 (15, 69) 212 17.4 165 13.6
100–200 8,067 29,194.92 0.88 34 (15, 66) 344 11.8 288 9.9
200–350 18,069 64,787.17 0.80 34 (15, 64) 432 6.7 375 5.8
350–500 18,661 63,856.75 0.62 31 (14, 61) 297 4.7 258 4.0
>500 26,170 85,179.33 0.44 29 (13, 57) 374 4.4 333 3.9
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HIV RNA, copies/mL <10000 20,793 68,189.42 0.49 29 (13, 58) 374 5.5 333 4.9
10000–100000 34,976 120,595.83 0.66 31 (14, 62) 798 6.6 671 5.6
>100000 22,324 80,326.67 0.79 34 (15, 65) 834 10.4 652 8.1
Sex Men 62,498 219,436.33 0.66 32 (15, 63) 1,769 8.1 1,449 6.6
Women 15,595 49,675.58 0.64 28 (12, 56) 237 4.8 207 4.2
Age, years <35 34,977 112,735.75 0.59 28 (13, 57) 257 2.3 215 1.9
35–50 32,120 118,048.75 0.69 35 (15, 66) 866 7.3 693 5.9
>50 10,996 38,327.42 0.76 33 (15, 63) 883 23.0 748 19.5
Transmission group Heterosexual 24,673 82,956.25 0.67 30 (13, 60) 462 5.6 379 4.6
Homosexual or bisexual 37,434 136,221.58 0.63 34 (16, 65) 433 3.2 344 2.5
Injecting drug user 3,361 9,018.58 0.58 20 (11, 44) 191 21.2 160 17.7
Other or unknown 12,625 40,915.50 0.71 29 (13, 59) 920 22.5 773 18.9
Table A5
CEPAC model input parameters sources, all time periods
Parameter Source
HIV natural history parameters
 Mean monthly CD4 count decrease when not on ART,
stratified by CD4 cell count and HIV RNA
Research in Access to Care for the Homeless
(REACH), San Francisco Men’s Health Study, and
Multi-Center AIDS Cohort Study (MACS) (32, 34,
35)
 Monthly risk of opportunistic infections (OIs), stratified by
CD4 cell count and OI
MACS (32); Walensky et al, 2010, Clin Infect Dis
(28)
 Monthly risk for acute OI-related death, among those with
OI, stratified by OI Walensky et al, 2010, Clin Infect Dis (28)
Efficacy of antiretroviral therapy
 Mean monthly CD4 count decrease when on ART, stratified
by time since treatment initiation Sax et al, 2010, Lancet (36)
 Viral suppression after 24 weeks, % Sax et al, 2010, Lancet (36)
 Monthly risk of late failure after initial viral suppression Sax et al, 2010, Lancet (36)
 Probability of treatment response Sax et al, 2010, Lancet (36); VOLTART trial(50)
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Survival and AIDS-free survival over follow-up estimated via the parametric g-formula
applied to HIV-CAUSAL data and each of 36 CEPAC calibration runs, varying on-
treatment multipliers for opportunistic infection incidence and chronic AIDS-related
mortality from 0 to 1 by 0.2.
CEPAC calibration runs (grey);, parametric g-formula estimates (black). All runs have
baseline on or after Jan 1, 2003. Survival (a–c), AIDS-free survival (d–f). Immediate
universal initiation(a,d); Initiation at CD4 <500 cells/μl(b,e); and Initiation at CD4 <350
cells/μl(c,f). CEPAC: Cost-Effectiveness of Preventing AIDS Complications model.
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7-year mortality (a) and combined mortality/AIDS risk (b) from CEPAC calibration runs for
baseline on or after Jan 1, 2003, varying on-ART multipliers for chronic AIDS-related
mortality and opportunistic infections from 0 to 1 by 0.2, stratified by treatment strategy.
Scales for each outcome shown below the strategy ‘CD4 < 500’. On-treatment multiplier for
chronic AIDS-related mortality increases from 0 to 1 down y-axis, on-treatment multiplier
for opportunistic infections increases from 0 to 1 across x-axis, following direction of
arrows. Black boxes indicate closest matchs to parametric g-formula estimates when
baseline is on or after Jan 1, 2003; grey boxes indicate 95% confidence interval for
parametric g-formula using 500 bootstrap samples. For the strategy ‘treat at CD4 < 350’, no
CEPAC runs resulted in risk estimates within the g-formula 95% confidence intervals for
either outcome. CEPAC: Cost-Effectiveness of Preventing AIDS Complications model.
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Table 3
Observed and estimated 7 year risk in each baseline cohort under no intervention, HIV-CAUSAL
Collaboration
Baseline period Outcome Observed risk at 7 years, % Estimated risk at 7 years, % (95% CI)**
Jan 1, 1996 – Dec 31, 1999 Mortality 9.5 9.3 (8.8, 9.9)
AIDS or death 16.2 16.6 (16.0, 17.3)
Jan 1, 2000 – Dec 31, 2002 Mortality 8.3 8.2 (7.8, 8.7)
AIDS or death 15.4 16.0 (15.4, 16.7)
Jan 1, 2003 onwards Mortality 4.6 4.4 (4.2, 4.7)
AIDS or death 9.5 9.5 (9.2, 9.8)
**
HIV-CAUSAL estimates based on the parametric g-formula adjusted for measured time-varying confounders (CD4 count, HIV-RNA and AIDS)
and baseline characteristics (calendar period and age of HIV diagnosis, risk group, gender, geographical origin, ethnicity and cohort). 95% CI:
confidence interval 95% CI: confidence interval
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